Global News and Digital Insights
for the Healthcare Industry

Sound Pharmaceuticals receives NIH’s grant to develop COVID-19 drug development

Sound pharmaceuticals has obtained a grant of $1.1m from the US National Institutes of Health (NIH) unit National Center for Advancing Translational Sciences (NCATS) for the development of an oral treatment of COVID-19, ebselen (SPI-1005). The grant will allow two trials of the said drug on 120 individuals suffering from moderate or severe levels of COVID-19. Ebselen has anti-viral as well as anti-inflammatory properties, belonging to the class of anti-inflammatory compounds with glutathione peroxide activity. SPI-1005 is still under scrutiny and is being investigated for neurotological, respiratory, and neuropsychiatric indications.  Along with the COVID-19 trials, the drug is also undergoing Phase III testing trials for Meniere’s Disease, and tobramycin ototoxicity in cystic fibrosis patients that deal with respiratory infections.

Read More from Pharmaceutical Technology

Share on facebook
Share on twitter
Share on linkedin